This opening segment introduces an OncLive program built around ASCO data on risk-guided treatment intensification and sequencing in EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Back
ASCO: Risk-Guided Intensification and Treatment Sequencing in EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Sandip Patel, MD, and Chul Kim, MD, review ASCO data on TP53 co-mutations, the TOP study, frontline therapy selection, and treatment sequencing strategies for patients with EGFR-mutated advanced non-small cell lung cancer.
ASCO: Risk-Guided Intensification and Treatment Sequencing in EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Episodes
All
All
This segment interprets the TOP study findings and their practice implications.
This segment turns from trial data to real-world practice, examining how quickly community oncology is adopting frontline combination regimens for EGFR-mutated NSCLC.
This segment covers central nervous system (CNS) involvement in EGFR-mutated NSCLC.
The segment introduces second-line sequencing, reviewing NCCN preferred options after frontline therapy.
The segment discusses consistency of re-biopsy being performed in the clinical setting along with key barriers to obtaining biopsies for patients.
Advertisement
Advertisement
Trending on OncLive
1
European Approval Is Sought for Lirafugratinib in FGFR2-Altered Metastatic Cholangiocarcinoma
2
FDA Approves Taletrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
3
Dr Bianchi on the Mechanism of Anselamimab in AL Amyloidosis
4
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
5